Anti-KIR3D antibodies
US9828427B2 · kind B2 · utility
8Cited by
1References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 28, 2015 |
| Grant date | Nov 28, 2017 |
| Priority date | — |
| Expiry date | Oct 28, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/732
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides antigen-binding proteins capable of binding to KIR3D polypeptides. The antibodies have increased activity in the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sézary Syndrome.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.